Daiichi Sankyo Company, Limited DSNKY
17.11 USD -0.23 (-1.33%)
Regular-session close
16.94 Day range 17.18
14.98 52-week range 24.77
- YTD
- -19.44%
- 1 year
- -24.36%
No chart data for this range yet.
- Market cap
- 31.18B
- EPS (ttm)
- 0.98
- P/E ratio
- 17.46
- YTD return
- -19.44%
- 1-year return
- -24.36%
- Volume
- 10.94K
- Avg volume
- 148.50K
- Open
- 16.94
- Previous close
- 17.34
- Day's range
- 16.94 – 17.18
- 52-week range
- 14.98 – 24.77
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2026 | Sep 30, 2026 | 0.2362 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | 0.2543 | 0.24 | -0.01 | -5.62% |
| May 11, 2026 | Mar 31, 2026 | 0.3317 | 0.1465 | -0.19 | -55.83% |
| Jan 29, 2026 | Dec 31, 2025 | 0.2504 | 0.3033 | +0.05 | +21.13% |
| Oct 31, 2025 | Sep 30, 2025 | 0.2986 | 0.1592 | -0.14 | -46.68% |
| Jul 31, 2025 | Jun 30, 2025 | 0.2337 | 0.3059 | +0.07 | +30.89% |
News
Daiichi Sankyo: Rising Oncology Pureplay Investment At Tantalizing Value
Daiichi Sankyo Company, Limited (DSNKY) Q2 2026 Earnings Call Transcript
Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1
Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO
COLL vs. DSNKY: Which Stock Is the Better Value Option?
Daiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
Merck, Daiichi Sankyo withdraw US application for lung cancer drug
Your note
Sign in to keep a note on DSNKY — it syncs with the Stock Master app.
